Skip to Content

'
Xifeng Wu

Present Title & Affiliation

Primary Appointment

Professor, Department of Epidemiology, Cancer Prevention and Population Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1155 Herman P. Pressler Blvd.
Unit Number: 1340
Houston, TX 77030
Room Number: CPB4.3209
Phone: (713) 745-2485
Fax: (713) 792-4657
Email: xwu@mdanderson.org

Education & Training

Degree-Granting Education

1994 The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, PHD, Epidemiology
1987 Zhejiang Medical University, Hangzhou, China, MS, Industrial Hygiene and Occupational Diseases
1984 Shanghai Medical University, Shanghai, China, MD, Medicine

Honors and Awards

2008-present Betty B. Marcus Chair in Cancer Prevention
2008-present Senior Fellow of the M. D. Anderson Research Trust, The University of Texas M. D. Anderson Cancer Center

Selected Publications

Peer-Reviewed Original Research Articles
1. Spitz MR, Amos CI, Dong Q, Lin J, Wu X. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst 100(21). e-Pub 10/28/2008. PMID: 18957677.
2. Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, Shete S. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 9(8):777-85, 2008. PMID: 18672213.
3. Yang H, Gu J, Lin X, Grossman HB, Ye Y, Dinney CP, Wu X. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 14(7):2236-44, 2008. PMID: 18381966.
4. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, Shete S, Etzel CJ. A risk model for prediction of lung cancer. J Natl Cancer Inst 99(9):715-26, 2007. PMID: 17470739.
5. Wu X, Lin J, Etzel CJ, Dong Q, Gorlova OY, Zhang Q, Amos CI, Spitz MR. Interplay between mutagen sensitivity and epidemiological factors in modulatinglung cancer risk. Int J Cancer 120(12):2687-95, 2007. PMID: 17290394.
6. Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, Gu J, Grossman HB, Wu X. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 13(9):2614-20, 2007. PMID: 17473191.
7. Wu X, Lin J, Grossman HB, Huang M, Gu J, Etzel CJ, Amos CI, Dinney CP, Spitz MR. Projecting Individualized Probabilities of Developing Bladder Cancer in Caucasians. J Clin Oncol 25(31):4974-81, 2007. PMID: 17971596.
8. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 78(3):464-79, 2006. PMID: 16465622.
9. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24(23):3789-98, 2006. PMID: 16785472.
10. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, Gu J, Grossman HB, Wu X. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 66(24):11644-8, 2006. PMID: 17178858.
11. Wu X, Spitz MR, Amos CI, Lin J, Shao L, Gu J, de Andrade M, Benowitz NL, Shields PG, Swan GE. Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res 66(12):5993-6, 2006. PMID: 16778168.
12. Lin J, Kadlubar FF, Spitz MR, Zhao H, Wu X. A modified host cell reactivation assay to measure DNA repair capacity for removing 4-aminobiphenyl adducts: a pilot study of bladder cancer. Cancer Epidemiol Biomarkers Prev 14(7):1832-6, 2005. PMID: 16030125.
13. Spitz MR, Wu X, Mills G. Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 23(2):267-75, 2005. PMID: 15637390.
14. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23(24):5746-56, 2005. PMID: 16110031.
15. Berman DM, Wang Y, Liu Z, Dong Q, Burke LA, Liotta LA, Fisher R, Wu X. A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res 64(18):6820-6, 2004. PMID: 15375002.
16. Zhu Y, Spitz MR, Amos CI, Lin J, Schabath MB, Wu X. An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res 64(6):2251-7, 2004. PMID: 15026370.
17. Rebbeck TR, Spitz M, Wu X. Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet 5(8):589-97, 2004. PMID: 15266341.
18. Schabath MB, Grossman HB, Delclos GL, Hernandez LM, Day RS, Davis BR, Lerner SP, Spitz MR, Wu X. Dietary carotenoids and genetic instability modify bladder cancer risk. J Nutr 134(12):3362-9, 2004. PMID: 15570038.
19. Wu X, Zhao H, Do KA, Johnson MM, Dong Q, Hong WK, Spitz MR. Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res 10(12 Pt 1):3988-95, 2004. PMID: 15217929.
20. Schabath MB, Spitz MR, Grossman HB, Zhang K, Dinney CP, Zheng PJ, Wu X. Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst 95(7):540-7, 2003. PMID: 12671022.
21. Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK, Spitz MR. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 95(16):1211-8, 2003. PMID: 12928346.
22. Wu X, Lippman SM, Lee JJ, Zhu Y, Wei QV, Thomas M, Hong WK, Spitz MR. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res 62(10):2813-8, 2002. PMID: 12019158.
23. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, Kadlubar FF, Spitz MR. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst 94(9):681-90, 2002. PMID: 11983757.
24. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 61:7825-9, 2001. PMID: 11691799.
25. Zhao H, Spitz MR, Tomlinson GE, Zhang H, Minna JD, Wu X. Gamma-radiation-induced G2 delay, apoptosis, and p53 response as potential susceptibility markers for lung cancer. Cancer Res 61:7819-24, 2001. PMID: 11691798.
26. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151-6, 1999. PMID: 9923856.
27. Wu X, Gu J, Hong WK, Lee JJ, Amos CI, Jiang H, Winn RJ, Fu KK, Cooper J, Spitz MR. Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst 90:1393-9, 1998. PMID: 9747870.
28. Wu X, Zhao Y, Honn SE, Tomlinson GE, Minna JD, Hong WK, Spitz MR. Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res 58:1605-8, 1998. PMID: 9563468.

Grant & Contract Support

Title: University of Texas SPORE in Lung Cancer. Project 2: Risk Prediction for Platinum-based Chemotherapy and Radiotherapy Outcome in Non-Small Cell Lung Cancer Patients
Funding Source: NIH/NCI
Role: Principal Investigator - Project 2
Principal Investigator: John Minna & Jack Roth
Duration: 9/1/2008 - 4/30/2013
 
Title: SPORE in Head and Neck Cancer, Project 2: Cancer Risk Assessment in Patients with Oral Premalignant Lesions: An Integrative Approach
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 8/1/2008 - 7/31/2012
 
Title: Telomere length, telomere maintenance gene, and bladder cancer risk
Funding Source: NIH/NCI
Role: Significant Contributor
Principal Investigator: Jian Gu
Duration: 7/1/2008 - 6/30/2012
 
Title: Molecular/Metabolic Pathways and Host Susceptibility Factors of Barrett’s Progression to Esophageal Adenocarcinoma
Funding Source: UT MD Anderson Cancer Center
Role: Co-Principal Investigator
Principal Investigator: Jaffer A. Ajani
Duration: 5/1/2008 - 4/30/2011
 
Title: Genome-Wide Association Analysis of Bladder Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2008 - 3/31/2013
 
Title: Genetic Instability and Risk for Esophageal Carcinoma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 3/10/2008 - 1/31/2013
 
Title: Inflammation gene polymorphisms and lung cancer risk
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Margaret R. Spitz
Duration: 1/1/2008 - 12/31/2012
 
Title: High-Density Association Analysis of Lung Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Christopher Amos
Duration: 7/1/2007 - 5/31/2011
 
Title: Genetic Polymorphisms in Inflammation Genes and Bladder Cancer Risk, no-cost extension
Funding Source: NIH/NCI
Role: Significant Contributor
Principal Investigator: Jian Gu
Duration: 7/1/2007 - 6/30/2009
 
Title: Genetic Polymorphisms in TRAIL Pathway as Susceptibility Markers for Lung Cancer, no-cost extension
Funding Source: NIH/NCI
Role: Significant Contributor
Principal Investigator: Jie Lin
Duration: 2/1/2007 - 1/31/2009
 
Title: Lung Cancer Chemoradiation: Predictors of Survival, no-cost extension
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 6/8/2005 - 4/30/2010
 
Title: Biobehavioral-Smoking Profiles in Mexican-American Youth, no-cost extension
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Margaret R. Spitz
Duration: 9/20/2004 - 8/31/2009
 
Title: Project 4: Molecular Epidemiology and Phamacogenomics in Oral Carcinogenesis, no-cost extension
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 8/1/2004 - 7/31/2010
 
Title: Adenocarcinoma of the Lung: Role of NNK susceptibility, no-cost extension
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Margaret R. Spitz
Duration: 4/1/2004 - 3/31/2009
 
Title: GU SPORE Project 2. Markers of Susceptibility as Predictors of Bladder Cancer Recurrence, no-cost extension
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/25/2001 - 8/31/2011
 
Title: Genetic Susceptibility to Bladder Cancer, no-cost extension
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2/22/1999 - 5/31/2009

Last updated: 9/10/2009